HOME Research Insight QIAGEN N.V. (Netherlands) and PerkinElmer, Inc. (U.S.) are Main Leading Players in Biomarkers Market

QIAGEN N.V. (Netherlands) and PerkinElmer, Inc. (U.S.) are Main Leading Players in Biomarkers Market

Key players in the biomarkers market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Enzo Biochem, Inc. (U.S.). The strong position of these companies in the market can primarily be attributed to their global presence and broad product portfolio. Other major players in the market include EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), and Cisbio Bioassays (France).

QIAGEN N.V. (Netherlands) is the largest player in the global biomarkers market. The company focuses on inorganic growth strategies such as partnerships and acquisitions to sustain its foothold in the market. For instance, in April 2016, QIAGEN N.V. partnered with Mirati Therapeutics, Inc. (U.S.) to co-develop and commercialize a companion diagnostic test for the usage of Mirati’s glesatinib, a targeted therapy under development for non-small cell lung cancer (NSCLC). With this partnership, the company focused on providing personalized treatment in NSCLC by detecting RNA biomarkers. The company focuses on expanding its product portfolio by acquisitions. For instance, in January 2015, the company acquired enzyme solutions unit of Enzymatics (U.S.). The company has a comprehensive portfolio of reagents that are widely used for NGS applications. This acquisition strengthened QIAGEN s NGS portfolio.

PerkinElmer, Inc. (U.S.) is the second-largest player in the global biomarkers market. The company focuses on inorganic and organic growth strategies such as collaborations and product launches to garner higher revenues in the market. For instance, in April 2016, PerkinElmer, Inc. collaborated with the Genome Institute of Singapore (GIS). The collaboration aimed to develop state-of-the-art high throughput screening platform to predict therapeutic response with real-time based tumor models to provide precision medicine in cancer research. With this collaboration, the company enhanced its precision medicine portfolio in oncology research. The company also focuses on product launches to strengthen its portfolio. For instance, in January 2014, the company introduced the AlphaLISA kits at the Third Annual Society for Laboratory Automation and Screening (SLAS) Conference at San Diego. The products are kits and reagents needed for metabolic disease research with Glucagon, Insulin, Leptin, C-peptide, and FGF21 biomarkers.

Merck Millipore (U.S.) is the third-largest player in the global biomarkers market. To remain competitive, the company adopted organic and inorganic growth strategies such as product launches and collaborations for enhancing its presence in the market. For instance, in December 2016, the company launched MILLIPLEX MAP Human High Sensitivity cytokine panel for human cytokine assays, with Luminex FLEXMAP 3D platform technology. The new assay measures multiple protein biomarkers in a single sample and provides faster results. This launch strengthened Merck’s product portfolio of immunoassays for human cytokines. Key players in the market are majorly focusing on product launches to maintain their positions the biomarkers market. This strategy accounted for 61% of the total number of strategic developments undertaken by key players in this market.

Related Reports:

Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support

US : 1-888-600-6441

Search reports